301232-45-1 Usage
Description
Tert-butyl 4-(3-ethoxy-3-oxopropyl)piperidine-1-carboxylate is a complex organic compound that features a piperidine ring, a carboxylate ester functional group, and includes elements such as tert-butyl and ethoxy groups. It is a member of the tertiary butyl group subset within alkyl compounds, and its properties, such as reactivity, stability, and toxicology, are dependent on its interactions with other compounds.
Uses
Used in Pharmaceutical Industry:
Tert-butyl 4-(3-ethoxy-3-oxopropyl)piperidine-1-carboxylate is used as an intermediate compound for the synthesis of various pharmaceuticals. Its unique structure allows it to be a key component in the development of new drugs, particularly in the context of medicinal chemistry where its reactivity and stability are critical for the formation of active pharmaceutical ingredients.
Used in Chemical Research:
In the field of chemical research, tert-butyl 4-(3-ethoxy-3-oxopropyl)piperidine-1-carboxylate serves as a model compound for studying the effects of different functional groups on the properties of organic compounds. Its structure provides a basis for understanding how changes in molecular architecture can influence reactivity and stability, which is essential for advancing the field of organic chemistry.
Used in Material Science:
Tert-butyl 4-(3-ethoxy-3-oxopropyl)piperidine-1-carboxylate is used as a building block in the development of new materials with specific properties. Its incorporation into polymers or other materials can alter their physical and chemical characteristics, making it a valuable component in the creation of advanced materials for various applications, such as in electronics or coatings.
Check Digit Verification of cas no
The CAS Registry Mumber 301232-45-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,0,1,2,3 and 2 respectively; the second part has 2 digits, 4 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 301232-45:
(8*3)+(7*0)+(6*1)+(5*2)+(4*3)+(3*2)+(2*4)+(1*5)=71
71 % 10 = 1
So 301232-45-1 is a valid CAS Registry Number.
301232-45-1Relevant articles and documents
Electrochemical Tandem Olefination and Hydrogenation Reaction with Ammonia
Zhang, Xiaofeng,Jiang, Runze,Cheng, Xu
, p. 16016 - 16025 (2021/08/24)
An electrochemical Horner-Wadsworth-Emmons/hydrogenation tandem reaction was achieved using ammonia as electron and proton donors. The reaction could give two-carbon-elongated ester and nitrile from aldehyde or ketones directly. This reaction could proceed with a catalytic amount of base or even without a base. The ammonia provides both the electron and proton for this tandem reaction and enables the catalyst-free hydrogenation of an α,β-unsaturated HWE intermediate. More than 40 examples were reported, and functional groups, including heterocycles and hydroxyl, were tolerated.
One-Pot, Tandem Wittig Hydrogenation: Formal C(sp3)-C(sp3) Bond Formation with Extensive Scope
Devlin, Rory,Jones, David J.,Mcglacken, Gerard P.
supporting information, p. 5223 - 5228 (2020/07/14)
A one-pot, tandem Wittig hydrogenation of aldehydes with stabilized ylides is reported, representing a formal C(sp3)-C(sp3) bond construction. The tandem reaction operates under mild conditions, is high yielding, and is broad in scope. Chemoselectivity for olefin reduction is observed, and the methodology is demonstrated in the synthesis of lapatinib analogues and a formal synthesis of (±)-cuspareine. Early insights suggest that the chemoselectivity observed in the reduction step is due to partial poisoning of the catalyst, after step one, thus adding to the power of the one-pot procedure.
Design, synthesis, and structure-activity relationships of potent GPIIb/IIIa antagonists: Discovery of FK419
Yamanaka, Toshio,Ohkubo, Mitsuru,Kuroda, Satoru,Nakamura, Hideko,Takahashi, Fumie,Aoki, Toshiaki,Mihara, Kayoko,Seki, Jiro,Kato, Masayuki
, p. 4343 - 4352 (2007/10/03)
The discovery of the non-peptide antiplatelet injectable agent FK419 is reported. Based on the β-turn structure of RGD peptide sequences in the α chain of fibrinogen, which binds the glycoprotein IIb/IIIa (GPIIb/IIIa) on the surface of platelets to induce